Show Summary Details
Page of

Myeloma and paraproteinaemias 

Myeloma and paraproteinaemias

Chapter:
Myeloma and paraproteinaemias
Author(s):

Robert A. Kyle

and S. Vincent Rajkumar

DOI:
10.1093/med/9780199204854.003.220405_update_002

Update:

Management—discussion of use of lenalidomide after autologous stem cell transplantation; detailed presentation of new data regarding treatment options in patients not eligible for stem cell transplantation; update on new novel agents.

Updated on 29 May 2014. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 23 August 2017

The paraproteinaemias are a group of neoplastic (or potentially neoplastic) diseases associated with the proliferation of a single clone of immunoglobulin-secreting plasma cells.

This asymptomatic condition of unknown cause is characterized by a serum paraprotein concentration under 30 g/l, less than 10% monoclonal plasma cells in the bone marrow, and no evidence of end-organ damage (CRAB) hypercalcaemia, renal insufficiency, anemia, and bone lesions related to the plasma cell proliferative process....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.